---
schema_version: "secwatch.filing_event.v1"
accession: "0001006837-25-000005"
form_type: "8-K"
ticker: "VATE"
cik: "0001006837"
company_name: "INNOVATE Corp."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:18:09.058448+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MediBeacon's Transdermal GFR Monitor and Sensor approved by China NMPA; Lumitrace under review

## Summary
- China NMPA approved MediBeacon TGFR Monitor and Sensor for kidney function assessment; Lumitrace injection still under review, target approval late 2025.
- FDA approved the TGFR system on Jan 17, 2025; MediBeacon developing next-gen TGFR with updated software.
- Published studies: eGFR misclassified 35% of CKD patients; transdermal GFR showed r²=0.90 correlation with plasma mGFR across skin types.
- MediBeacon CEO highlighted partnership with Huadong Medicine for China rollout of the TGFR system.

## SEC filing metadata
- accession: 0001006837-25-000005
- form_type: 8-K
- ticker: VATE
- cik: 0001006837
- company_name: INNOVATE Corp.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006837/000100683725000005/0001006837-25-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006837/000100683725000005/hchc-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001006837-25-000005
- JSON: https://secwatch.observer/filing/0001006837-25-000005.json
- Plain text: https://secwatch.observer/filing/0001006837-25-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.